Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On

The President and COO of Adaptive Biotechnologies Corporation reported the sale of 38,120 shares for about $554,000, based on a weighted average transaction price of $14.53 per share across April 1–2, 2026. This sale represented 7.85% of Rubinstein's direct Common Stock holdings, reducing her direct position to 447,202 shares post-transaction.